Judging value for money and improving decision making

OHE Lunchtime Seminar with Alistair McGuire, 3rd February 2020. The seminar will present some preliminary thoughts on the promises offered by personalised medicine that it will allow efficient identification of different target groups and consequently more effective treatment.

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.

Henderson N., Errea M., Skedgel C. and Jofre-Bonet, M.

Consulting Report
January 2020

In light of concerns 

Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential for using real world evidence to improve the efficiency of the Malaysian health system.

Meet some of the OHE team at the Health Economists’ Study Group (HESG) Winter 2020 meeting in Newcastle, 6-8 January 2020.

In 1994 Ben van Hout introduced the concept of the cost effectiveness acceptability curve (CEAC). In the 25 years since, the CEAC has become a standard part of health economic evaluations and incorporated into health technology assessment guidelines. Professors Nancy Devlin and Andrew Briggs spoke at a reception at ISPOR Europe this year to celebrate these contributions. As 2019 comes to a close, OHE reflects on 25 years of the CEAC.

OHE presented at the Global AMR R&D Hub Board of Members Meeting in Paris, on adapting HTA and payment mechanisms to incentivise new drugs to tackle AMR. This presentation was based on research by OHE, funded by the Wellcome Trust.

OHE, in collaboration with RAND Europe, University College London (UCL) and University of Manchester (UoM), has been awarded a new research grant from Cancer Research UK in partnership with Greater Manchester Health & Social Care Partnership (GMHSCP) to further explore the potential of implementing outcome-based payments for cancer treatments.

A new OHE Research Paper summarises the findings of a project funded by the Wellcome Trust on innovative HTA methods and contracting for antibiotics. The paper provides an overview of the current state of HTA and contracting for antibiotics in five European countries, reviews recent proposals in the literature for revising HTA approaches and explores the associated implementation opportunities and challenges.

Neri, M., Hampson, G., Henshall, C. and Towse, A.

Research Paper
September 2019

Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel, global antibiotic development pipelines are weak. Various R&D incentives have been proposed to address the challenges associated to low economic returns from investment in antibiotics. Value assessment methods recognising the value of new antibiotics to the whole health system are needed to help match the size of the required monetary incentives to the value that they offer.

Pages

Subscribe to RSS - Judging value for money and improving decision making